CD4 and cancer: CD4+ T-cells specific to the WEDLT209-228 epitope were enriched 250-fold within MCC tumor samples compared to blood and exhibited diverse T-cell receptor (TCR) repertoires, therefore suggesting in vivo antigen recognition and therapeutic potential of CD4+ T-cell responses targeting of specific cancers [62].